These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 38047536)
21. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Marsh DJ; Learoyd DL; Andrew SD; Krishnan L; Pojer R; Richardson AL; Delbridge L; Eng C; Robinson BG Clin Endocrinol (Oxf); 1996 Mar; 44(3):249-57. PubMed ID: 8729519 [TBL] [Abstract][Full Text] [Related]
22. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Ruiz A; Antiñolo G; Fernández RM; Eng C; Marcos I; Borrego S Clin Endocrinol (Oxf); 2001 Sep; 55(3):399-402. PubMed ID: 11589684 [TBL] [Abstract][Full Text] [Related]
23. Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation. Qi XP; Lin GB; Chen B; Li F; Cao ZL; Zheng WH; Zhao JQ Endocr Metab Immune Disord Drug Targets; 2021; 21(3):554-560. PubMed ID: 32660411 [TBL] [Abstract][Full Text] [Related]
24. Oncological features of sporadic vs. hereditary pediatric medullary thyroid cancer. Machens A; Lorenz K; Weber F; Dralle H Endocrine; 2024 Sep; 85(3):1091-1095. PubMed ID: 39003661 [TBL] [Abstract][Full Text] [Related]
29. Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience. Wei S; LiVolsi VA; Montone KT; Morrissette JJ; Baloch ZW Endocr Pathol; 2016 Dec; 27(4):359-362. PubMed ID: 27379493 [TBL] [Abstract][Full Text] [Related]
30. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830 [TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513 [TBL] [Abstract][Full Text] [Related]
32. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320 [TBL] [Abstract][Full Text] [Related]
33. Medullary Thyroid Carcinomas Classified According to the International Medullary Carcinoma Grading System and a Surveillance, Epidemiology, and End Results-Based Metastatic Risk Score: A Correlation With Genetic Profile and Angioinvasion. Torricelli F; Santandrea G; Botti C; Ragazzi M; Vezzani S; Frasoldati A; Ghidini A; Giordano D; Zanetti E; Rossi T; Nicoli D; Ciarrocchi A; Piana S Mod Pathol; 2023 Sep; 36(9):100244. PubMed ID: 37307881 [TBL] [Abstract][Full Text] [Related]
34. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130 [TBL] [Abstract][Full Text] [Related]
35. Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study. Erdogan MF; Gürsoy A; Ozgen G; Cakir M; Bayram F; Ersoy R; Algün E; Cetinarslan B; Cömlekçi A; Kadioglu P; Balci MK; Yetkin I; Kabalak T; Erdogan G J Endocrinol Invest; 2005 Oct; 28(9):806-9. PubMed ID: 16370559 [TBL] [Abstract][Full Text] [Related]
36. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277 [TBL] [Abstract][Full Text] [Related]
37. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Romei C; Ugolini C; Cosci B; Torregrossa L; Vivaldi A; Ciampi R; Tacito A; Basolo F; Materazzi G; Miccoli P; Vitti P; Pinchera A; Elisei R Thyroid; 2012 May; 22(5):476-81. PubMed ID: 22404432 [TBL] [Abstract][Full Text] [Related]
38. Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy. Darabi S; Adeyelu T; Elliott A; Sukari A; Hodges K; Abdulla F; Zuazo CE; Wise-Draper T; Wang T; Demeure MJ J Am Coll Surg; 2024 Jul; 239(1):50-60. PubMed ID: 38651727 [TBL] [Abstract][Full Text] [Related]
39. External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort. Vissio E; Maletta F; Fissore J; Osella Abate S; Retta F; Brizzi MP; Piovesan A; Rossetto Giaccherino R; Volante M; Papotti M Endocr Pathol; 2022 Sep; 33(3):359-370. PubMed ID: 35583706 [TBL] [Abstract][Full Text] [Related]
40. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]